Kymera’s oral “Dupixent-in-a-pill” KT-621 shows strong early eczema results

Kymera Therapeutics; KT-621; Dupixent-in-a-pill; oral STAT6 degrader; atopic dermatitis; eczema; BroADen Phase 1b trial; Dupixent rival; Type 2 inflammation; early clinical data

ViTAA Medical Secures FDA 510(k) Clearance for AiORTA Plan, Launching Its Hyper-Precise Aortic Care Platform

ViTAA Medical; FDA 510(k) clearance; AiORTA Plan; hyper-precise aortic care; automated aortic surgery planning; vascular AI; preoperative measurement automation; cloud-based healthcare; aortic aneurysm segmentation; clinical workflow improvement